Trial Profile
A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon(R) in Patients With Nephropathic Cystinosis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Nephropathic cystinosis
- Focus Pharmacokinetics; Registrational
- Sponsors Raptor Pharmaceutical Inc
- 26 Jun 2014 New trial record